Adverse drug reactions and expected effects to therapy with subcutaneous mistletoe extracts (Viscum album L.) in cancer patients

Evidence-based Complementary and Alternative Medicine

Volumn 2014, Issue , 2014, Pages

  Steele, Megan L ^a   Axtner, Jan ^a   Happe, Antje ^a   Kröz, Matthias ^a,b,c   Matthes, Harald ^a,b   Schad, Friedemann ^a  

^a Havelhoehe Research Institute   (Germany)

^b Hospital Gemeinschaftskrankenhaus Havelhoehe   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; VISCUM ALBUM EXTRACT; VISCUM ALBUM LECTIN;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; BURNING SENSATION; CANCER PATIENT; CANCER STAGING; CHILL; DEPRESSED BLOOD PRESSURE; DIARRHEA; DISEASE SEVERITY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; EOSINOPHILIA; ERYTHEMA; FAINTNESS; FATIGUE; FEMALE; FEVER; GERMANY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IMMUNOREACTIVITY; INCIDENCE; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; INJECTION SITE URTICARIA; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALAISE; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PRURITUS; RISK FACTOR; SKIN INDURATION; URTICARIA; VERY ELDERLY; VISCUM ALBUM; VOMITING;

EID: 84896813504     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2014/724258     Document Type: Article

References (67)

1. Horneber M., Bueschel G., Dennert G., Less D., Zwahlen M., How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integrative Cancer Therapies 2012 11 3 187 203 10.1177/1534735411423920
2. Kienle G. S., Kiene H., Albonico H. U., Anthroposophic medicine: health technology assessment report-short version. Forschende Komplementarmedizin 2006 13 supplement 2 7 18 2-s2.0-33745757524 10.1159/000093481
3. Horneber M. A., Bueschel G., Huber R., Linde K., Rostock M., Mistletoe therapy in oncology. Cochrane Database of Systematic Reviews 2008 2 CD003297 2-s2.0-44949261074
4. Zeller J. W., Schwabe U., Paffrath D., Immuntherapeutika und zytostatika. Arzneimittelverordnungs-Report 2004 2004 Berlin, Germany Springer 609 624
5. Seifert G., Jesse P., Laengler A., Reindl T., Lüth M., Lobitz S., Henze G., Prokop A., Lode H. N., Molecular mechanisms of mistletoe plant extract-induced apoptosis in acute lymphoblastic leukemia in vivo and in vitro. Cancer Letters 2008 264 2 218 228 2-s2.0-43049176801 10.1016/j.canlet.2008.01. 036
6. Gardin N. E., Immunological response to mistletoe (Viscum album L.) in cancer patients: a four-case series. Phytotherapy Research 2009 23 3 407 411 2-s2.0-61449189674 10.1002/ptr.2643
7. Hostanska K., Hajto T., Spagnoli G. C., Fischer J., Lentzen H., Herrman R., A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. Natural Immunity 1995 14 5-6 295 304 2-s2.0-0029548382
8. Huber R., Claßen K., Werner M., Klein R., In vitro immunoreactivity towards lectin-rich or viscotoxin-rich mistletoe (Viscum album L.) extracts iscador applied to healthy individuals: a randomised double-blind placebo controlled study. Arzneimittel-Forschung 2006 56 6 447 456 2-s2.0-33748656280
9. Jaggy C., Musielski H., Urech K., Schaller G., Quantitative determination of lectins in mistletoe preparations. Arzneimittel-Forschung 1995 45 8 905 909 2-s2.0-0029090289
10. Ostermann T., Raak C., Büssing A., Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review. BMC Cancer 2009 9, article 451 2-s2.0-74249108509 10.1186/1471-2407-9-451
11. Kienle G. S., Glockmann A., Schink M., Kiene H., Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. Journal of Experimental and Clinical Cancer Research 2009 28 1, article no. 79 2-s2.0-68349116044 10.1186/1756-9966-28-79
12. Beuth J., Schneider B., Schierholz J. M., Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled multicenter comparative Epidemiological Cohort Study. Anticancer Research 2008 28 1 523 527 2-s2.0-40549134157
13. Melzer J., Iten F., Hostanska K., Saller R., Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. Forschende Komplementarmedizin 2009 16 4 217 226 2-s2.0-70149121373 10.1159/000226249
14. Büssing A., Raak C., Ostermann T., Quality of life and related dimensions in cancer patients treated with mistletoe extract (Iscador): a meta-analysis. Evidence-based Complementary and Alternative Medicine 2012 2012 8 2-s2.0-80052753545 10.1155/2012/219402 219402
15. Matthes H., Friedel W. E., Bock P. R., Zänker K. S., Molecular mistletoe therapy: friend or foe in established antitumor protocols? a multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer. Current Molecular Medicine 2010 10 4 430 439 2-s2.0-77953523650 10.2174/156652410791317057
16. Eisenbraun J., Scheer R., Kröz M., Schad F., Huber R., Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistletoe extract. Phytomedicine 2011 18 2-3 151 157 2-s2.0-78651322711 10.1016/j.phymed.2010.06.013
17. Heusser P., Braun S. B., Bertschy M., Burkhard R., Ziegler R., Helwig S., Van Wegberg B., Cerny T., Palliative in-patient cancer treatment in an anthroposophic hospital: II. Quality of life during and after stationary treatment, and subjective treatment benefits. Forschende Komplementarmedizin 2006 13 3 156 166 2-s2.0-33745745944 10.1159/000092448
18. Myers S. P., Cheras P. A., The other side of the coin: safety of complementary and alternative medicine. Medical Journal of Australia 2004 181 4 222 225 2-s2.0-4444335521
19. Tascilar M., de Jong F. A., Verweij J., Mathijssen R. H. J., Complementary and alternative medicine during cancer treatment: beyond innocence. Oncologist 2006 11 7 732 741 2-s2.0-33746612104 10.1634/ theoncologist.11-7-732
20. Cassileth B. R., Deng G., Complementary and alternative therapies for cancer. Oncologist 2004 9 1 80 89 2-s2.0-1642579678 10.1634/theoncologist.9-1-80
21. Kim K. C., Yook J. H., Eisenbraun J., Kim B. S., Huber R., Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma-a randomized, controlled pilot study. BMC Complementary and Alternative Medicine 2012 12, article 172 10.1186/1472-6882-12-172
22. Huber R., Lüdtke H., Wieber J., Beckmann C., Safety and effects of two mistletoe preparations on production of Interleukin-6 and other immune parameters-a placebo controlled clinical trial in healthy subjects. BMC Complementary and Alternative Medicine 2011 11, article 116 2-s2.0-82055175627 10.1186/1472-6882-11-116
23. Schad F., Teodoridis C., Albrecht U., Network oncology (NO)-a European approach to health service research on cancer treatment with focus on concurrent use of complementary therapies. European Journal of Integrative Medicine 2008 1 supplement 1 12 13
24. Schad F., Axtner J., Happe A., Network oncology (NO)-a clinical cancer register for health services research and the evaluation of integrative therapeutic interventions in anthroposophic medicine. Research in Complementary Medicine 2013 20 353 360 10.1159/000356204
25. Schad F., Pissarek J., Albrecht U., Matthes H., QuaDoSta (quality assurance, documentation and statistics)-a flexible, platform-independent, open source database for oncological documentation. Cancer Research and Clinical Oncology 2004 130 supplement op 785
26. Jeschke E., Schad F., Pissarek J., Matthes B., Albrecht U., Matthes H., QuaDoSta-a freely configurable system which facilitates multi-centric data collection for healthcare and medical research. GMS Medizinische Informatik, Biometrie und Epidemiologie 2007 3 2
27. R Core Team, R: A language and environment for statistical computing. in R Foundation for Statistical Computing, 2012
28. UMC, Safety monitoring of medicinal products: guidelines for setting up and running a pharmacovigilance centre. http://www.who.int/medicinedocs
29. ICH, E2A: clinical safety data management: definitions and standards for expedited reporting. http://www.ich.org
30. CTEP, Common terminology criteria for adverse events. http://ctep.cancer.gov/protocolDevelopment
31. Arzneimittelinformation AbnobaVISCUM. 2007, http://www.abnoba.de
32. Iscador: Anthroposophisches Arzneimittel. Fachinformation des Arzneimittel-Kompendium der Schweiz. 2007, http://www.weleda.de
33. Helixor: Anthroposophische Arzneimittel. Fachinformation des Arzneimittel-Kompendium der Schweiz. 2007, http://www.helixor.de
34. Concato J., Peduzzi P., Holford T. R., Feinstein A. R., Importance of events per independent variable in proportional hazards analysis I. Background, goals, and general strategy. Journal of Clinical Epidemiology 1995 48 12 1495 1501 2-s2.0-0029584326 10.1016/0895-4356(95)00510-2
35. Peduzzi P., Concato J., Feinstein A. R., Holford T. R., Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimates. Journal of Clinical Epidemiology 1995 48 12 1503 1510 2-s2.0-0029613841 10.1016/0895-4356(95)00048-8
36. Peduzzi P., Concato J., Kemper E., Holford T. R., Feinstem A. R., A simulation study of the number of events per variable in logistic regression analysis. Journal of Clinical Epidemiology 1996 49 12 1373 1379 2-s2.0-0030474271 10.1016/S0895-4356(96)00236-3
37. Bock P. R., Friedel W. E., Hanisch J., Karasmann M., Schneider B., Efficacy and safety of long-term complementary treatment with standardized european mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma / results of a multicenter, comparative, epidemiological Cohort study in Germany and Switzerland. Arzneimittel-Forschung 2004 54 8 456 466 2-s2.0-4344630940
38. Kienle G. S., Grugel R., Kiene H., Safety of higher dosages of Viscum album L. in animals and humans-systematic review of immune changes and safety parameters. BMC Complementary and Alternative Medicine 2011 11, article 72 2-s2.0-80052025838 10.1186/1472-6882-11-72
39. CIOMS, Guidelines for Preparing Core Clinical-Safety InFormation on Drugs 1999 2nd Geneva, Switzerland Council for International Organizations of Medical Sciences
40. Radenkovic M., Ivetic V., Popovic M., Brankovic S., Gvozdenovic L., Effects of mistletoe (Viscum album L., Loranthaceae) extracts on arterial blood pressure in rats treated with atropine sulfate and hexocycline. Clinical and Experimental Hypertension 2009 31 1 11 19 2-s2.0-60549098089 10.1080/10641960802409820
41. Penter R., Methodische aspekte zu einer goetheanistisch- anthroposophischen klinischen forschung am beispiel der entwicklung der mistelfiebertherapie. Der Merkurstab 2002 5 350 368
42. Adaramoye O., Amanlou M., Habibi-Rezaei M., Pasalar P., Ali M., Methanolic extract of African mistletoe (Viscum album) improves carbohydrate metabolism and hyperlipidemia in streptozotocin-induced diabetic rats. Asian Pacific Journal of Tropical Medicine 2012 5 6 427 433 2-s2.0-84860642705 10.1016/S1995-7645(12)60073-X
43. Frederick E., Kayode A., Slyvester U., Evaluation of the methanolic extract of mistletoe (Tapinanthus bangwensis) leaves grown on orange trees for the phytochemical properties and its physiological effects on streptozotocin induced diabetes mellitus in laboratory animals. World Applied Sciences Journal 2010 9 9 975 979
44. Tabali M., Jeschke E., Bockelbrink A., Witt C. M., Willich S. N., Ostermann T., Matthes H., Educational intervention to improve physician reporting of adverse drug reactions (ADRs) in a primary care setting in complementary and alternative medicine. BMC Public Health 2009 9, article 274 2-s2.0-69149097902 10.1186/1471-2458-9-274
45. Tabali M., Ostermann T., Jeschke E., Witt C. M., Matthes H., Adverse drug reactions for CAM and conventional drugs detected in a network of physicians certified to prescribe CAM drugs. Journal of Managed Care Pharmacy 2012 18 6 427 438
46. Süsskind M., Thürmann P. A., Lüke C., Jeschke E., Tabali M., Matthes H., Ostermann T., Adverse drug reactions in a complementary medicine hospital: a prospective, intensified surveillance study. Evidence-based Complementary and Alternative Medicine 2012 2012 8 2-s2.0-84856388485 10.1155/2012/320760 320760
47. Fischer S., Scheffler A., Kabelitz D., Stimulation of the specific immune system by mistletoe extracts. Anti-Cancer Drugs 1997 8 supplement 1 S33 S37 2-s2.0-0030985844
48. Stein G., Henn W., von Laue H., Berg P., Modulation of the cellular and humoral immune responses of tumor patients by mistletoe therapy. European Journal of Medical Research 1998 3 4 194 202 2-s2.0-0032495685
49. von Laue H. B., Henn W., Zeitphänomene der krebskrankheit. Deutsche Zeitschrift für Onkologie 1991 23 64 73
50. Kokolus K. M., Hong C., Repasky E. A., Feeling too hot or cold after breast cancer: is it just a nuisance or a potentially important prognostic factor? International Journal of Hyperthermia 2010 26 7 662 680 2-s2.0-77956897143 10.3109/02656736.2010.507235
51. Bessell E. M., Selby C., Ellis I. O., Severe hypoglycaemia caused by raised insulin-like growth factor II in disseminated breast cancer. Journal of Clinical Pathology 1999 52 10 780 781 2-s2.0-0032886609
52. Valdagni R., Amichetti M., Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymphnodes in stage IV head and neck patients. International Journal of Radiation Oncology Biology Physics 1994 28 1 163 169 2-s2.0-0028054799
53. Jones E. L., Oleson J. R., Prosnitz L. R., Samulski T. V., Vujaskovic Z., Yu D., Sanders L. L., Dewhirst M. W., Randomized trial of hyperthermia and radiation for superficial tumors. Journal of Clinical Oncology 2005 23 13 3079 3085 2-s2.0-19644369686 10.1200/JCO.2005.05.520
54. van der Zee J., González González D., van Rhoon G. C., van Dijk J. D. P., van Putten W. L. J., Hart A. A. M., Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. The Lancet 2000 355 9210 1119 1125 2-s2.0-0342545492
55. Sugimachi K., Kuwano H., Ide H., Toge T., Saku M., Oshiumi Y., Chemotherapy combined with or without hyperthermia for patients with oesophageal carcinoma: a prospective randomized trial. International Journal of Hyperthermia 1994 10 4 485 493 2-s2.0-0028302747
56. Sugimachi K., Kitamura K., Baba K., Ikebe M., Morita M., Matsuda H., Kuwano H., Hyperthermia combined with chemotherapy and irradiation for patients with carcinoma of the oesophagus-a prospective randomized trial. International Journal of Hyperthermia 1992 8 3 289 295 2-s2.0-0026604306
57. Peer A. J., Grimm M. J., Zynda E. R., Repasky E. A., Diverse immune mechanisms may contribute to the survival benefit seen in cancer patients receiving hyperthermia. Immunologic Research 2010 46 1-3 137 154 2-s2.0-77949401920 10.1007/s12026-009-8115-8
58. Saller R., Kramer S., Iten F., Melzer J., Scheer R., Bauer H., Becker V., Unerwünschte wirkungen der misteltherapie bei tumorpatienten-eine systematische Übersicht. Fortschritte in der Misteltherapie: Aktueller Stand der Forschung und klinische Anwendung 2005 Essen, Germany KVC 367 403
59. Martin R. M., Biswas P. N., Freemantle S. N., Pearce G. L., Mann R. D., Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: Analysis of 48 Cohort studies. British Journal of Clinical Pharmacology 1998 46 5 505 511 2-s2.0-0031760880 10.1046/j.1365-2125.1998.00817.x
60. Zopf Y., Rabe C., Neubert A., Gaßmann K. G., Rascher W., Hahn E. G., Brune K., Dormann H., Women encounter ADRs more often than do men. European Journal of Clinical Pharmacology 2008 64 10 999 1004 2-s2.0-53249086098 10.1007/s00228-008-0494-6
61. Ali Y. S., Daamen N., Giris J., Orthostatic intolerance: a disorder of young women. Obstetrical and Gynecological Survey 2000 55 4 251 259 10.1097/00006254-200004000-00025
62. Rasmussen L., Arvin A., Chemotherapy-induced immunosuppression. Environmental Health Perspectives 1982 43 21 25 2-s2.0-0020003349
63. Rouas-Freiss N., Moreau P., Menier C., Carosella E. D., HLA-G in cancer: a way to turn off the immune system. Seminars in Cancer Biology 2003 13 5 325 336 2-s2.0-0742322659 10.1016/S1044-579X(03)00023-3
64. Mansky P. J., Grem J., Wallerstedt D. B., Monahan B. P., Blackman M. R., Mistletoe and gemcitabine in patients with advanced cancer: a model for the phase I study of botanicals and botanical-drug interactions in cancer therapy. Integrative Cancer Therapies 2003 2 4 345 352 2-s2.0-0344393561 10.1177/1534735403259061
65. Mansky P. J., Wallerstedt D. B., Sannes T., NCCAM/NCI phase I study of mistletoe extract and gemcitabine in patients with advanced solid tumors. Journal of Clinical Oncology 2010 28 15 supplement 2559
66. Piao B. K., Wang Y. X., Xie G. R., Mansmann U., Matthes H., Beuth J., Lin H. S., Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Research 2004 24 1 303 309 2-s2.0-1442350530
67. Reidenberg M. M., Lowenthal D. T., Adverse nondrug reactions. The New England Journal of Medicine 1968 279 13 678 679 2-s2.0-0014431185